
    
      It is estimated that 50 patients who met the study criteria will be enrolled in 1 years and
      treated with Camrelizumab plus Apatinib in SYSUCC. The investigators will follow up and
      collect subjects' data to evaluate the efficacy and safety of treatment, including objective
      response rate (ORR) and Progression-free Survival (PFS) and Overall Survival (OS), until
      disease progression or death. Histopathology and multi-omics data analysis will be used to
      explore potential biomarkers of treatment response.
    
  